Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883742 | 0.92 | DRD2 (0.62) | SCN9ADRD2DRD3ESR1KDM4E | |
| SCHEMBL6142233 | 0.85 | KCNH2 (0.64) | KDM4EALDH1A1LMNATSHRMEN1 | |
| SCHEMBL5883813 | 0.82 | HDAC1 (0.57) | DRD2DRD3ESR1KDM4ETSHR | |
| Hydrochloric Acid SCHEMBL8021990 | 0.82 | P2RX7 (0.58) | DRD2DRD3ESR1KDM4EALDH1A1 | |
| SCHEMBL5884145 | 0.79 | NPY1R (0.55) | SCN9ADRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL5883743 | 0.79 | HDAC1 (0.51) | SCN9ADRD2DRD3ESR1LMNA | |
| SCHEMBL5883766 | 0.77 | HDAC1 (0.52) | DRD2DRD3ESR1OPRM1OPRD1 | |
| SCHEMBL5883566 | 0.77 | LTA4H (0.52) | DRD2DRD3ESR1OPRM1OPRD1 | |
| SCHEMBL29056560 | 0.76 | P2RX7 (0.67) | DRD2DRD3ESR1OPRK1KDM4E | |
| SCHEMBL16699112 | 0.75 | SCN9A (1.00) | SCN9AALDH1A1MEN1KMT2ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022714-B2 | Aryl substituted benzimidazoles and their use as sodium channel blockers | EURO-CELTIQUE S.A. (LU) | 2006-04-04 | — | — | US | claimed |
| EP-1532119-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2005-05-25 | — | — | EP | claimed |
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | PURDUE PHARMA L.P. | 2004-07-08 | — | — | US | claimed |
| WO-2004011439-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | claimed |
| US-7022714-B2 | Aryl substituted benzimidazoles and their use as sodium channel blockers | EURO-CELTIQUE S.A. (LU) | 2006-04-04 | — | — | US | disclosed |
| EP-1532119-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2005-05-25 | — | — | EP | disclosed |
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | PURDUE PHARMA L.P. | 2004-07-08 | — | — | US | disclosed |
| WO-2004011439-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | CACNA1S, CACNA1I, SCN1A | SCN9A 61/4885DRD2 1360/4885DRD3 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.